These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11687320)

  • 1. Activity of faropenem against resistant isolates of Streptococcus pneumoniae.
    Black JA; Moland ES; Chartrand SA; Thomson KS
    Diagn Microbiol Infect Dis; 2001; 41(1-2):89-92. PubMed ID: 11687320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of faropenem and 21 other compounds against 385 different genetically characterized isolates of antibiotic-resistant Streptococcus pneumoniae.
    Schmitz FJ; Boos M; Mayer S; Verhoef J; Milatovic D; Fluit AC
    J Antimicrob Chemother; 2001 Jul; 48(1):148-52. PubMed ID: 11418531
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 250 invasive Streptococcus pneumoniae isolates from France.
    Decousser JW; Pina P; Picot F; Allouch PY
    Eur J Clin Microbiol Infect Dis; 2003 Sep; 22(9):561-5. PubMed ID: 12942341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Investigation of the antibacterial activity of faropenem against Streptococcus pneumoniae].
    Hanaki H; Inaba Y; Hiramatsu K
    Jpn J Antibiot; 1999 Sep; 52(9):563-70. PubMed ID: 10746191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro bactericidal activities of new oral penem, faropenem against the various clinical isolates].
    Matsuzaki K; Nishiyama T; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 May; 52(5):431-8. PubMed ID: 10480050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antibacterial activity of beta-lactams and non-beta-lactams against Streptococcus pneumoniae isolates from Sydney, Australia.
    Gosbell IB; Fernandes LA; Fernandes CJ
    Pathology; 2006 Aug; 38(4):343-8. PubMed ID: 16916725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of faropenem and imipenem for ciprofloxacin-resistant bacteria.
    Piddock LJ; Johnson MM; Webber MA
    J Antimicrob Chemother; 2003 Sep; 52(3):500-2. PubMed ID: 12917244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of faropenem against respiratory pathogens.
    du Plessis M; Capper TP; Klugman KP
    J Antimicrob Chemother; 2002 Mar; 49(3):575-7. PubMed ID: 11864964
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains.
    Jones RN; Critchley IA; Whittington WL; Janjic N; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):311-7. PubMed ID: 16269221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents.
    Jones ME; Blosser-Middleton RS; Critchley IA; Karlowsky JA; Thornsberry C; Sahm DF
    J Antimicrob Chemother; 2003 Jan; 51(1):196-9. PubMed ID: 12493818
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel.
    Stone KC; Dagan R; Arguedas A; Leibovitz E; Wang E; Echols RM; Janjic N; Critchley IA
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2230-5. PubMed ID: 17387157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro and in vivo activities of cefpodoxime proxetil against penicillin-resistant Streptococcus pneumoniae].
    Kawada H; Kitayama A; Fukuoka T; Ishii C; Abe T; Kakuta M; Domon H; Ohya S; Utsui Y
    Jpn J Antibiot; 1999 Aug; 52(8):533-40. PubMed ID: 10587878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.
    Kosowska-Shick K; McGhee P; Appelbaum PC
    Antimicrob Agents Chemother; 2009 May; 53(5):2176-80. PubMed ID: 19237649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
    Black J; Moland ES; Chartrand SA; Thomson KS
    Diagn Microbiol Infect Dis; 2001 Mar; 39(3):195-7. PubMed ID: 11337189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
    Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.
    Hovde LB; Rotschafer SE; Ibrahim KH; Gunderson B; Hermsen ED; Rotschafer JC
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):265-7. PubMed ID: 12729997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of ertapenem against drug-resistant Streptococcus pneumoniae and other respiratory pathogens from 12 Asian countries.
    Song JH; Ko KS; Lee MY; Park S; Baek JY; Lee JY; Heo ST; Kwon KT; Ryu SY; Oh WS; Peck KR; Lee NY
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):445-50. PubMed ID: 16949783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of beta-lactams, macrolides, telithromycin, and fluoroquinolones against clinical isolates of Streptococcus pneumoniae: correlation between drug resistance and genetic characteristics.
    Yamaguchi T; Hashikita G; Takahashi S; Itabashi A; Yamazaki T; Maesaki S
    J Infect Chemother; 2005 Oct; 11(5):262-4. PubMed ID: 16258826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.
    Hadley JA; Tillotson GS; Tosiello R; Echols RM
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):923-37. PubMed ID: 17181408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN; Sader HS; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.